研飞ivySCI (青藤学术）

Molecular Cancer Therapeutics

短名	Mol. Cancer Ther.
Journal Impact	5.47
国际分区	ONCOLOGY(Q1)
期刊索引	SCI Q2中科院 2 区

ISSN	1535-7163, 1538-8514
h-index	199
国内分区	医学(2区)医学肿瘤学(2区)

MOLECULAR CANCER THERAPEUTICS 将专注于对以下领域的癌症治疗具有影响的基础研究：实验性癌症治疗、分子靶点鉴定、化学预防靶点、新模型、癌症化学和药物发现、分子和细胞药理学、肿瘤分子分类，以及生物信息学和计算分子生物学。该杂志为这些新兴学科提供了一个出版论坛，专门关注癌症研究。论文经过严格审查，只有那些报告新颖、及时、重要的研究结果并符合高科学价值标准的论文才会被接受发表。

期刊主页投稿网址

涉及主题	生物遗传学医学化学内科学生物化学癌症研究癌症基因细胞生物学细胞凋亡药理学免疫学细胞培养病理信号转导体外外科有机化学受体磷酸化细胞
出版信息	出版商: American Association for Cancer Research Inc.，出版周期: Monthly，期刊类型: journal
基本数据	创刊年份: 2001，原创研究文献占比: 95.00%，自引率:0.00%， Gold OA占比: 32.75%
平均审稿周期	网友分享经验：平均3月
平均录用比例	网友分享经验：约50%

期刊引文格式

这些示例是对学术期刊文章的引用，以及它们应该如何出现在您的参考文献中。

并非所有期刊都按卷和期组织其已发表的文章，因此这些字段是可选的。有些电子期刊不提供页面范围，而是列出文章标识符。在这种情况下，使用文章标识符而不是页面范围是安全的。

只有1位作者的期刊

有2位作者的期刊

有3位作者的期刊

有5位以上作者的期刊

书籍引用格式

以下是创作和编辑的书籍的参考文献的示例。

学位论文引用格式

网页引用格式

这些示例是对网页的引用，以及它们应该如何出现在您的参考文献中。

专利引用格式

Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules

2024-9-11

Targeting the synthetic lethal relationship between FOCAD and TUT7 represents a potential therapeutic opportunity for TUT4/7 small molecule inhibitors in cancer

2024-9-5

TR-107, An Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells

2024-9-5

Selected Articles from This Issue

2024-9-4

Correction: Oleanolic Acid Inhibits Epithelial–Mesenchymal Transition of Hepatocellular Carcinoma by Promoting iNOS Dimerization

2024-9-4

Immunoproteasome activation expands the MHC class I immunopeptidome, unmasks neoantigens and enhances T-cell antimyeloma activity

2024-8-30

Fatty acid derivatization and cyclization of the immunomodulatory peptide RP-182 targeting CD206high macrophages improves anti-tumor activity

2024-8-30

SC134-TCB targeting fucosyl-GM1, a T cell engaging antibody with potent anti-tumour activity in preclinical small-cell lung cancer models

2024-8-26

Preclinical Characterization of ARX517, a Site-specific Stable PSMA-Targeted Antibody Drug Conjugate for Treatment of Metastatic Castration-Resistant Prostate Cancer

2024-8-22

Dual A2A/ A2B adenosine receptor antagonist M1069 counteracts immuno-suppressive mechanisms of adenosine and reduces tumor growth in vivo

2024-8-20

Trametinib potentiates anti-PD-1 efficacy in tumors established from chemotherapy-primed pancreatic cancer cells

2024-8-20

Targeting PDHK1 by DCA to restore NK cell function in hepatocellular carcinoma

2024-8-20

Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

2024-8-16

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models

2024-8-16

A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation

2024-8-16

Harnessing the Potential of FAP-IL-12mut TMEkine™ for Targeted and Enhanced Anti-tumor Responses

2024-8-16

KRAS-driven Tumorigenesis and KRAS-driven Therapy in Pancreatic Adenocarcinoma

2024-8-9

Novel Inhibition of Central Carbon Metabolism Pathways by Rac and CDC42 inhibitor MBQ167 and Paclitaxel

2024-8-1

Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers

2024-8-1

Selected Articles from This Issue

2024-8-1

Identification of ATP-Competitive Human CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function

2024-7-26

Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2

2024-7-23

NAD+ metabolic enzyme inhibitor as radiosensitizer for malignant meningioma and its modulation of P53 expression

2024-7-23

Anti-Claudin-2 Antibody-Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis

2024-7-11

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer

2024-7-10

Blocking M2-like macrophage polarization using decoy oligodeoxynucleotide-based gene therapy prevents immune evasion for pancreatic cancer treatment

2024-7-5

Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11

2024-7-5

Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer

2024-7-4

Prognostic significance of SASP-related gene signature of radiation therapy in head and neck squamous cell carcinoma

2024-7-3

Enhancing neutrophil cytotoxicity of a panel of clinical EGFR antibodies by Fc engineering to IgA3.0

2024-7-3

YAP1 suppression by ZDHHC7 is associated with ferroptosis resistance and poor prognosis in ovarian clear cell carcinoma

2024-7-3

Selected Articles from This Issue

2024-7-2

Tumor microenvironment reprogramming improves nanomedicine-based chemo-immunotherapy in sarcomas

2024-6-28

FZ-AD005, A Novel DLL3-Targeted Antibody-drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models

2024-6-28

The discovery of a potent PARP1 inhibitor Senaparib

2024-6-26

Radiation and chemo-sensitizing effects of DNA-PK inhibitors are proportional in tumors and normal tissues

2024-6-24

PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer

2024-6-21

Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors

2024-6-18

IL-15/IL-15Rα-Fc fusion protein XmAb24306 potentiates activity of CD3 bispecific antibodies through enhancing T cell expansion

2024-6-17

Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation

2024-6-12

SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity

2024-6-11

MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells

2024-6-10

Abstract B002: POLB knockout is synthetic lethal with PARP inhibition leading to complete and durable responses in BRCA-mutant tumor xenografts

2024-6-10

Abstract A013: NF1 loss is syntetic lethal with Trastuzumab emtansine

2024-6-10

Abstract A020: TP53 mutation and prediction of platinum response in BRCA-mutated ovarian cancer: A prospective case-series analysis

2024-6-10

Abstract B006: Data-driven discoveries of molecular mechanism and therapeutic vulnerabilities of CDK12 mutant tumors

2024-6-10

Abstract B015: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in <i>KRAS</i> mutant cancers

2024-6-10

Abstract B016: Discovering novel synthetic lethal relationships with large-scale cellular simulations

2024-6-10

Abstract A009: Synthetic lethality in the context of STAG2-mutant Ewing sarcoma

2024-6-10

Abstract PR011: Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition

2024-6-10

帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理

投稿经验分享

分享我的经验，帮你走得更远

Molecular Cancer Therapeutics

期刊引文格式

只有1位作者的期刊

有2位作者的期刊

有3位作者的期刊

有5位以上作者的期刊

书籍引用格式

学位论文引用格式

网页引用格式

专利引用格式

最新文章

Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules

Targeting the synthetic lethal relationship between FOCAD and TUT7 represents a potential therapeutic opportunity for TUT4/7 small molecule inhibitors in cancer

TR-107, An Agonist of Caseinolytic Peptidase Proteolytic Subunit, Disrupts Mitochondrial Metabolism and Inhibits the Growth of Human Colorectal Cancer Cells

Selected Articles from This Issue

Correction: Oleanolic Acid Inhibits Epithelial–Mesenchymal Transition of Hepatocellular Carcinoma by Promoting iNOS Dimerization

Immunoproteasome activation expands the MHC class I immunopeptidome, unmasks neoantigens and enhances T-cell antimyeloma activity

Fatty acid derivatization and cyclization of the immunomodulatory peptide RP-182 targeting CD206high macrophages improves anti-tumor activity

SC134-TCB targeting fucosyl-GM1, a T cell engaging antibody with potent anti-tumour activity in preclinical small-cell lung cancer models

Preclinical Characterization of ARX517, a Site-specific Stable PSMA-Targeted Antibody Drug Conjugate for Treatment of Metastatic Castration-Resistant Prostate Cancer

Dual A2A/ A2B adenosine receptor antagonist M1069 counteracts immuno-suppressive mechanisms of adenosine and reduces tumor growth in vivo

Trametinib potentiates anti-PD-1 efficacy in tumors established from chemotherapy-primed pancreatic cancer cells

Targeting PDHK1 by DCA to restore NK cell function in hepatocellular carcinoma

Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment

Separable cell cycle arrest and immune response elicited through pharmacological CDK4/6 and MEK inhibition in RASmut disease models

A DXd/TLR7-Agonist Dual-Conjugate Anti-HER2 ADC Exerts Robust Antitumor Activity Through Tumor Cell Killing and Immune Activation

Harnessing the Potential of FAP-IL-12mut TMEkine™ for Targeted and Enhanced Anti-tumor Responses

KRAS-driven Tumorigenesis and KRAS-driven Therapy in Pancreatic Adenocarcinoma

Novel Inhibition of Central Carbon Metabolism Pathways by Rac and CDC42 inhibitor MBQ167 and Paclitaxel

Discovery of RGT-018: A Potent, Selective, and Orally Bioavailable SOS1 Inhibitor for KRAS-Driven Cancers

Selected Articles from This Issue

Identification of ATP-Competitive Human CMG Helicase Inhibitors for Cancer Intervention that Disrupt CMG-Replisome Function

Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2

NAD+ metabolic enzyme inhibitor as radiosensitizer for malignant meningioma and its modulation of P53 expression

Anti-Claudin-2 Antibody-Drug Conjugates for the Treatment of Colorectal Cancer Liver Metastasis

AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer

Blocking M2-like macrophage polarization using decoy oligodeoxynucleotide-based gene therapy prevents immune evasion for pancreatic cancer treatment

Discovery of Monovalent Direct Degraders of BRD4 That Act Via the Recruitment of DCAF11

Pretargeted radioimmunotherapy with the novel anti-oxMIF/HSG bispecific antibody ON105 results in significant tumor regression in murine models of cancer

Prognostic significance of SASP-related gene signature of radiation therapy in head and neck squamous cell carcinoma

Enhancing neutrophil cytotoxicity of a panel of clinical EGFR antibodies by Fc engineering to IgA3.0

YAP1 suppression by ZDHHC7 is associated with ferroptosis resistance and poor prognosis in ovarian clear cell carcinoma

Selected Articles from This Issue

Tumor microenvironment reprogramming improves nanomedicine-based chemo-immunotherapy in sarcomas

FZ-AD005, A Novel DLL3-Targeted Antibody-drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models

The discovery of a potent PARP1 inhibitor Senaparib

Radiation and chemo-sensitizing effects of DNA-PK inhibitors are proportional in tumors and normal tissues

PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer

Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors

IL-15/IL-15Rα-Fc fusion protein XmAb24306 potentiates activity of CD3 bispecific antibodies through enhancing T cell expansion

Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation

SMG5 Inhibition Restrains Hepatocellular Carcinoma Growth and Enhances Sorafenib Sensitivity

MYTX-011: A pH-Dependent Anti–c-MET Antibody–Drug Conjugate Designed for Enhanced Payload Delivery to c-MET–Expressing Tumor Cells

Abstract B002: POLB knockout is synthetic lethal with PARP inhibition leading to complete and durable responses in BRCA-mutant tumor xenografts

Abstract A013: NF1 loss is syntetic lethal with Trastuzumab emtansine

Abstract A020: TP53 mutation and prediction of platinum response in BRCA-mutated ovarian cancer: A prospective case-series analysis

Abstract B006: Data-driven discoveries of molecular mechanism and therapeutic vulnerabilities of CDK12 mutant tumors

Abstract B015: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in <i>KRAS</i> mutant cancers

Abstract B016: Discovering novel synthetic lethal relationships with large-scale cellular simulations

Abstract A009: Synthetic lethality in the context of STAG2-mutant Ewing sarcoma

Abstract PR011: Inhibiting eIF4E phosphorylation sensitizes triple-negative breast cancer to CDK4/6 inhibition

帮你贴心管理全部的文献.css-5myebc{font-size:14px;font-weight:var(--chakra-fontWeights-normal);margin-top:var(--chakra-space-1);margin-bottom:var(--chakra-space-1);}研飞ivySCI，高效的论文管理

帮你贴心管理全部的文献
研飞ivySCI，高效的论文管理